30 July 2018 | News
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a‘state-of-the-art’ manufacturing facility for the production and packaging of sterile dry powder injection in Dubai.
Wockhardt, an India-based pharmaceutical company and Biotech major, sets up its first facility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a ‘state-of-the-art’ manufacturing facility for the production and packaging of sterile dry powder injection in Dubai. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production.
Antimicrobial resistance (AMR) the ability of infections to resist antibiotics to work against it is increasingly recognized as growing global health problem. Infections caused by antimicrobial resistant strains of bacteria-also called “superbugs” are unlikely to respond to standard treatments resulting in prolonged illness and a greater risk to health, and severely impacting clinical outcomes, leading to further higher healthcare costs due to consumption of healthcare resources.
Wockhardt currently has 5 novel antibiotic drugs in advanced stages of global clinical development which will be effective against these “superbugs” threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the 5 novel antibiotic drugs.
Wockhardt Bio AG manufacturing facility is designed to meet standards of various international regulatory agencies and the standards as set by the Local Ministry of Health. The facility meets the needs of Aseptic Dry Powder Injectable manufacturing and filling with a high quality operation. This facility is dedicated to launch its novel New Chemical Entities in the Antibiotics segment to the world from UAE.
The facility is spread over 10,000 sq. meters of space, self-sufficient for handling Warehousing, Manufacturing Operations, Product Testing and Product Stability.
The facility is equipped with best-in-class and fully automated manufacturing equipment and clean utility systems. The design takes into account the requirements for Product & Personnel Safety and Product Quality with complete close transfers and high levels of sterility assurances.